Abstract:Background: Defective mitochondria and aberrant brain mitochondrial bioenergetics are consistent features in syndromic intellectual disability disorders, such as Rett syndrome (RTT), a rare neurologic disorder that severely affects mainly females carrying mutations in the X-linked MECP2 gene. A pool of CB1 cannabinoid receptors (CB1R), the primary receptor subtype of the endocannabinoid system in the brain, is located on brain mitochondrial membranes (mtCB1R), where it can locally regulate energy production, synaptic transmission and memory abilities through the inhibition of the intra-mitochondrial protein kinase A (mtPKA). In the present study, we asked whether an overactive mtCB1R-mtPKA signaling might underlie the brain mitochondrial alterations in RTT and whether its modulation by systemic administration of the CB1R inverse agonist rimonabant might improve bioenergetics and cognitive defects in mice modeling RTT. Methods: Rimonabant (0.3 mg/kg/day, intraperitoneal injections) was administered daily to symptomatic female mice carrying a truncating mutation of the Mecp2 gene and its effects on brain mitochondria functionality, systemic oxidative status, and memory function were assessed. Results: mtCB1R is overexpressed in the RTT mouse brain. Subchronic treatment with rimonabant normalizes mtCB1R expression in RTT mouse brains, boosts mtPKA signaling, and restores the defective brain mitochondrial bioenergetics, abnormal peripheral redox homeostasis, and impaired cognitive abilities in RTT mice. Limitations: The lack of selectivity of the rimonabant treatment towards mtCB1R does not allow us to exclude that the beneficial effects exerted by the treatment in the RTT mouse model may be ascribed more broadly to the modulation of CB1R activity and distribution among intracellular compartments, rather than to a selective effect on mtCB1R-mediated signaling. The low sample size of few experiments is a further limitation that has been addressed replicating the main findings under different experimental conditions. Conclusions: The present data identify mtCB1R overexpression as a novel molecular alteration in the RTT mouse brain that may underlie defective brain mitochondrial bioenergetics and cognitive dysfunction.

Boosting Serotonin Synthesis Is Not Sufficient to Improve Motor Coordination of Mecp2 Heterozygous Mouse Model of Rett Syndrome

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Motor Training Improves Coordination and Anxiety in Symptomaticmecp2-Null Mice Despite Impaired Functional Connectivity Within the Motor Circuit

MeCP2 Deficiency Impairs Motor Cortical Circuit Flexibility Associated with Motor Learning

Dysregulated Cortical Synaptic Plasticity under Methyl-Cpg Binding Protein 2 Deficiency and Its Implication in Motor Impairments

Choline Rescues Behavioural Deficits in a Mouse Model of Rett Syndrome by Modulating Neuronal Plasticity

Loss of MeCP2 in Aminergic Neurons Causes Cell-Autonomous Defects in Neurotransmitter Synthesis and Specific Behavioral Abnormalities

Unraveling autophagic imbalances and therapeutic insights in Mecp2-deficient models

A Partial Loss of Function Allele of Methyl-Cpg-binding Protein 2 Predicts a Human Neurodevelopmental Syndrome.

Leptin antagonism improves Rett syndrome phenotype in symptomatic male Mecp2-null mice

β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome

Anaplerotic Triheptanoin Diet Enhances Mitochondrial Substrate Use to Remodel the Metabolome and Improve Lifespan, Motor Function, and Sociability in MeCP2-Null Mice

Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome

Dendrimer nanotherapy targeting of glial dysfunction improves inflammation and neurobehavioral phenotype in adult female Mecp2-heterozygous mouse model of Rett syndrome

Loss and Gain of MeCP2 Cause Similar Hippocampal Circuit Dysfunction That is Rescued by Deep Brain Stimulation in a Rett Syndrome Mouse Model.

Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome

Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome

Serotonin 5-HT1B receptor-mediated behavior and binding in mice with the overactive and dysregulated serotonin transporter Ala56 variant

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome